Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fegan

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
Bone Marrow Transplantation|August 1, 1995
In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantationC Fegan, H Thomas, R Bailey-Wood, et al.
British Journal of Haematology|April 17, 2004
Guidelines on the diagnosis and management of chronic lymphocytic leukaemiaD Oscier, C Fegan, P Hillmen, et al.
Leukemia & Lymphoma|October 29, 2002
ATM mutations in sporadic lymphoid tumoursT Stankovic, G S Stewart, P Byrd, et al.
British Journal of Haematology|March 23, 1999
Haemostatic and fibrinolytic responses to bone marrow transplantationS A Brown, S V Davies, C Fegan, et al.
Clinical and Laboratory Haematology|November 13, 2001
The outcome of ambulatory DVT management using a multidisciplinary approachP Rose, D Bell, E S Green, et al.
Leukemia & Lymphoma|August 23, 2006
The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemiaN C Pemberton, S Paneesha, L Hiller, et al.
European Journal of Haematology|February 1, 1995
All trans retinoic acid enhances human LAK activityC Fegan, R Bailey-Wood, S Coleman, et al.
Journal of Medical Engineering & Technology|June 22, 2022
User attitudes towards virtual home assessment technologiesV Lanfranchi, N Jones, J Read, et al.
Leukemia|February 3, 2006
CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38- counter-partsC Pepper, P Brennan, S Alghazal, et al.
Eye (London, England)|August 21, 2003
The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusionP M Dodson, J Haynes, J Starczynski, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
Bone Marrow Transplantation|August 1, 1995
In vitro LAK (lymphokine activated killer) activity following autologous peripheral blood stem cell is significantly greater than that following autologous bone marrow and allogeneic bone marrow transplantationC Fegan, H Thomas, R Bailey-Wood, et al.
British Journal of Haematology|April 17, 2004
Guidelines on the diagnosis and management of chronic lymphocytic leukaemiaD Oscier, C Fegan, P Hillmen, et al.
Leukemia & Lymphoma|October 29, 2002
ATM mutations in sporadic lymphoid tumoursT Stankovic, G S Stewart, P Byrd, et al.
British Journal of Haematology|March 23, 1999
Haemostatic and fibrinolytic responses to bone marrow transplantationS A Brown, S V Davies, C Fegan, et al.
Clinical and Laboratory Haematology|November 13, 2001
The outcome of ambulatory DVT management using a multidisciplinary approachP Rose, D Bell, E S Green, et al.
Leukemia & Lymphoma|August 23, 2006
The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemiaN C Pemberton, S Paneesha, L Hiller, et al.
European Journal of Haematology|February 1, 1995
All trans retinoic acid enhances human LAK activityC Fegan, R Bailey-Wood, S Coleman, et al.
Journal of Medical Engineering & Technology|June 22, 2022
User attitudes towards virtual home assessment technologiesV Lanfranchi, N Jones, J Read, et al.
Leukemia|February 3, 2006
CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38- counter-partsC Pepper, P Brennan, S Alghazal, et al.
Eye (London, England)|August 21, 2003
The platelet glycoprotein Ia/IIa gene polymorphism C807T/G873A: a novel risk factor for retinal vein occlusionP M Dodson, J Haynes, J Starczynski, et al.
Pageof 5